IGC Pharma, Inc. (IGC) earnings
IGC earnings moved a median of -0.85% by the close. Quarterly and annual IGC reports and results, each read against the price at its own news timestamp. Back to the IGC overview →
16 measured IGC earnings events.
Where these IGC earnings landedvs 16 measured IGC earnings reactions
| Middle 50% of IGC earnings reactions | -1.82% to +1.15% |
|---|---|
| Median reaction (to close) | -0.85% |
| Measured reactions | 16 |
Point-in-time · zero look-ahead
Half of the 16 IGC earnings events with a measured close landed between -1.82% and +1.15%; 31% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure | Press release | -1.82% | -1.82% | |
| Form 10-Q IGC Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.82% | -1.82% | |
| IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment | Press release | +1.70% | -0.32% | |
| Form 10-Q IGC Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.69% | -0.69% | |
| IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." | Press release | +2.38% | +14.77% | |
| Form 10-Q IGC Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -1.64% | -6.98% | |
| IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50." | Press release | +1.90% | +15.74% | |
| Form 10-Q IGC Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.41% | -0.03% | |
| Form 10-K IGC Pharma, Inc. For: Mar 31 | SEC filing · Form 10-K | -0.16% | -1.61% | |
| IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25" | Press release | -0.97% | +4.42% | |
| Form 10-Q IGC Pharma, Inc. For: Dec 31 | SEC filing · Form 10-Q | +0.03% | -1.58% | |
| Form 10-Q IGC Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.06% | +1.77% | |
| Form 10-Q IGC Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.56% | -1.01% | |
| Form 10-K IGC Pharma, Inc. For: Mar 31 | SEC filing · Form 10-K | — | +0.95% | |
| Form 10-Q IGC Pharma, Inc. For: Dec 31 | SEC filing · Form 10-Q | -3.28% | -2.79% | |
| Form 10-Q IGC Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.65% | -4.10% |
Keep exploring
More IGC: analyst actions → · SEC filings → · IGC overview →